Skip to main content

Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst

Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.